optimized neoantigen synthetic long peptide vaccine

The optimized neoantigen synthetic long peptide (SLP) vaccine is a personalized cancer immunotherapy designed to elicit robust T-cell responses against tumor-specific mutations (neoantigens). These vaccines are manufactured by identifying patient-specific tumor mutations through next-generation sequencing and bioinformatics prediction of immunogenic epitopes. Synthetic peptides—typically 20 or more amino acids in length—are then produced to match these predicted neoepitopes. The SLPs are administered with adjuvants to enhance immune activation. The mechanism of action involves direct priming of the immune system, particularly antigen-presenting cells such as dendritic cells, which process and present the peptides on MHC molecules to activate both CD4+ and CD8+ T cells. This leads to targeted recognition and destruction of cancer cells expressing the corresponding mutated antigens[6][7][9]. Clinical trials have demonstrated that these vaccines can induce strong tumor-specific T-cell responses with a favorable safety profile[6][8]. They are being investigated primarily for advanced solid tumors including melanoma, pancreatic cancer, glioblastoma, non-small cell lung cancer, and bladder cancer[4][7][8].

Other names

optimized neoantigen SLP vaccinepersonalized neoantigen SLP vaccinesynthetic long peptide neoantigen vaccine